focus -WSS

focus

author：Wikipedia 2025-10-01 04:44:58 - browse：7164

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Empower primary care with adequate payments and technology

WSS

Hospitals consider fixing cancer drug shortages on their own

Novel spinal cord stimulator treats paralysis without surgery

Hospitals consider fixing cancer drug shortages on their own

As billionaires fund anti

AI for drug discovery: Experts on separating hype from reality

Acelyrin, a rare IPO success, stumbles in its first big test

focus

focus

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Food makers to regulators: Ultra

Walensky prepares to leave CDC — and Congress — behind

Food makers tried to stack nutrition panel with preferred experts

As demand for Covid shots wanes, Moderna seeks its next success

PEPFAR is under serious threat — and so is global health

The cancer drug shortage isn’t new — and neither are the solutions

Has Bernie Sanders reached the limit of his pharma bullying effort?

Medicare details structure of new drug price negotiation program

PBM executives asked to testify by House panel

hotspot

Private equity could exacerbate cardiology's overuse problem, experts fear

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Regeneron agrees to White House price limits on anti

Is it ever OK for doctors to lie to their patients?

Can gargling with Listerine treat gonorrhea of the mouth?

Food makers to regulators: Ultra

explore

focus

hotspot

hotspot